Anti-cancer compounds licensed for development
New compounds developed at the U of S that alter the action of conventional cancer-fighting drugs to reduce harm to otherwise normal cells will be developed by Mississauga-based YM BioSciences Inc. under a worldwide licensing agreement announced in August.
Biochemistry Professor Rob Warrington said in a news release the compounds, called propargylamines, also increase the ability of cancer drugs to kill tumour cells. They have also been shown to overcome drug-resistance traits that cause problems in cancer treatment.
“It’s very exciting for me after all these years of lab work to see that these compounds may finally be evaluated clinically,” said Warrington. “Our hope is that they’ll increase survival rates in cancer patients, but of course we won’t know that for several years.”
The U of S owns patents on the compounds and their uses, and will get
royalties through the licensing agreement.